Want to see AU:CYV full AI Analyst Report?
CYV Stock Chart & Stats
AU$0.60
-AU$0.04(-5.10%)
At close: 4:00 PM EST
AU$0.60
-AU$0.04(-5.10%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.62
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
AU$16.42M
Enterprise ValueAU$774.17M
Total Cash (Recent Filing)AU$22.13M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)<0.1
Beta2.12
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,367,978,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-3.65
Price to Sales (P/S)29392.74
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$200.00K
Bulls Say, Bears Say
Bulls Say
Lead Clinical-stage AssetOpthea's lead biologic targets VEGF-C/D and is being developed as a complement to anti-VEGF-A therapies for wet AMD and DME. That positions the company in large, chronic retinal markets where combination therapy can sustain durable demand and attract partnership or licensing interest.
Positive Gross Profit TrendPositive gross profit in recent years implies manufacturing and COGS dynamics that could support attractive unit economics if commercialization occurs. This durable margin signal reduces the incremental cash required per unit sold and improves long-run scalability of revenues.
Eliminated Reported DebtRemoving reported debt materially lowers fixed financial obligations and near-term solvency risk, improving flexibility to pursue partnerships, equity financing, or milestone-based deals without immediate debt servicing constraints, a durable enhancement to financial optionality.
Bears Say
Persistent Heavy Cash BurnSustained ~-159M operating cash burn year-to-year indicates ongoing high cash consumption for R&D and operations. This creates a continuous need for external financing, raising dilution risk and limiting the company's ability to self-fund development beyond a few quarters absent partnerships or capital raises.
Negative Equity And Shrinking AssetsNegative shareholders' equity and a marked asset decline reflect accumulated losses and a diminished balance sheet capacity. This weak capital base reduces negotiating leverage with partners and heightens reliance on dilutive financing or deal structures to fund late-stage development and commercialization.
Pre-commercial Revenue DependencyAs a clinical-stage biotech with effectively no commercial revenue, Opthea's future cash flow fundamentally depends on binary clinical and regulatory outcomes. That structural dependence makes long-term revenue visibility low and ties company viability to trial success and eventual market access or partner commercialization.
CYV FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.01 and its highest was AU$0.61 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is AU$16.42M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2026 which is in 45 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Mar 01, 2026. The company reported AU$0.263 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is 0.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,367,978,100 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of AU$0.263 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in AU:CYV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opthea Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.45%
12-Months-Change
Fundamentals
Return on Equity
44.23%
Trailing 12-Months
Asset Growth
-83.74%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---